Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2017

23.08.2017 | Clinical Study

Association between hospital volume and receipt of treatment and survival in patients with glioblastoma

verfasst von: Matthew Koshy, David J. Sher, Michael Spiotto, Zain Husain, Herb Engelhard, Konstantin Slavin, Martin K. Nicholas, Ralph R. Weichselbaum, Chad Rusthoven

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The relation between hospital volume and outcomes for patients with glioblastoma is unknown. We undertook this study to determine the effect of hospital volume on treatment received and its effect on survival in patients with glioblastoma. We included patients from the National Cancer Database diagnosed with a glioblastoma from 2006 to 2013. Hospital volume was calculated by examining the treating facilities average number of cases per year and grouping them into tertiles: (low < 9.25, medium 9.26–23.88, and high ≥ 23.39). Treatment was defined as receiving any type of therapeutic surgery, radiation or chemotherapy. Using regression models we examined the relation between hospital volume to treatment received and survival with adjustment for clinical, socioeconomic and institutional factors. The study included 68,726 patients of which 91.8% received treatment. Among patients diagnosed at low volume facilities, 90.1% received treatment versus 94.2% in high volume facilities (p < 0.0001). Compared to low volume centers, the odds ratio of receiving any treatment was 1.01 (CI 95% CI: 0.95–1.09) and 1.43 (95% CI: 1.31–1.55) for medium volume and high volume facilities, respectively. On multivariate analysis for survival among those who received treatment, the hazard of mortality was decreased at high volume (HR 0.92, 95% CI 0.89–0.94) facilities compared to low volume facilities. Patients diagnosed with glioblastoma at a high volume facility (≥23.39 cases per year) have an increased likelihood of receiving treatment. Furthermore, glioblastoma patients may significantly improve their survival by choosing to receive care at a high-volume hospital.
Literatur
1.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi: 10.1016/S1470-2045(09)70025-7 CrossRefPubMed Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi: 10.​1016/​S1470-2045(09)70025-7 CrossRefPubMed
2.
Zurück zum Zitat Linz U (2009) Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi: 10.1002/cncr.24950 CrossRef Linz U (2009) Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466. doi: 10.​1002/​cncr.​24950 CrossRef
3.
5.
Zurück zum Zitat Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. doi: 10.3171/jns.2001.95.2.0190 CrossRefPubMed Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. doi: 10.​3171/​jns.​2001.​95.​2.​0190 CrossRefPubMed
6.
Zurück zum Zitat Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003) Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129:477–484. doi: 10.1007/s00432-003-0471-5 CrossRefPubMed Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003) Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129:477–484. doi: 10.​1007/​s00432-003-0471-5 CrossRefPubMed
10.
Zurück zum Zitat Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687CrossRefPubMed Meyer FB, Bates LM, Goerss SJ, Friedman JA, Windschitl WL, Duffy JR, Perkins WJ, O’Neill BP (2001) Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo Clin Proc 76:677–687CrossRefPubMed
11.
Zurück zum Zitat Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W et al (2017) Short-course radiation plus Temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. doi: 10.1056/NEJMoa1611977 CrossRefPubMed Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W et al (2017) Short-course radiation plus Temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. doi: 10.​1056/​NEJMoa1611977 CrossRefPubMed
12.
Zurück zum Zitat Luchtenborg M, Riaz SP, Coupland VH, Lim E, Jakobsen E, Krasnik M, Page R, Lind MJ, Peake MD, Moller H (2013) High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol 31:3141–3146. doi:10.1200/JCO.2013.49.0219 CrossRefPubMed Luchtenborg M, Riaz SP, Coupland VH, Lim E, Jakobsen E, Krasnik M, Page R, Lind MJ, Peake MD, Moller H (2013) High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol 31:3141–3146. doi:10.​1200/​JCO.​2013.​49.​0219 CrossRefPubMed
13.
Zurück zum Zitat Begg CB, Cramer LD, Hoskins WJ, Brennan MF (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747–1751.CrossRefPubMed Begg CB, Cramer LD, Hoskins WJ, Brennan MF (1998) Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280:1747–1751.CrossRefPubMed
14.
Zurück zum Zitat Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM et al (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33:156–164. doi:10.1200/JCO.2014.56.5218 CrossRefPubMed Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM et al (2015) Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 33:156–164. doi:10.​1200/​JCO.​2014.​56.​5218 CrossRefPubMed
15.
Zurück zum Zitat Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF et al (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 94:683–690 doi: 10.1016/j.ijrobp.2015.12.008 CrossRefPubMed Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF et al (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 94:683–690 doi: 10.​1016/​j.​ijrobp.​2015.​12.​008 CrossRefPubMed
19.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.​1056/​NEJMoa043330 CrossRefPubMed
20.
21.
Zurück zum Zitat Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF (2002) The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 131:6–15CrossRefPubMed Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF (2002) The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 131:6–15CrossRefPubMed
22.
Zurück zum Zitat Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137. doi:10.1056/NEJMsa012337 CrossRefPubMed Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137. doi:10.​1056/​NEJMsa012337 CrossRefPubMed
Metadaten
Titel
Association between hospital volume and receipt of treatment and survival in patients with glioblastoma
verfasst von
Matthew Koshy
David J. Sher
Michael Spiotto
Zain Husain
Herb Engelhard
Konstantin Slavin
Martin K. Nicholas
Ralph R. Weichselbaum
Chad Rusthoven
Publikationsdatum
23.08.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2017
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2598-2

Weitere Artikel der Ausgabe 3/2017

Journal of Neuro-Oncology 3/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.